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Abstract

Author Manuscript

Pomegranate juice with a high content of polyphenols, pomegranate extract, ellagic acid, and
urolithin A, have anti-oxidant and anti-obesity effects in humans. Pomegranate juice extends
lifespan of Drosophila melanogaster. Caenorhabditis elegans (C. elegans) (n = 6) compared to the
control group in each treatment, lifespan was increased by pomegranate juice in wild type (N2,
56 %, P < 0.001) and daf-16 mutant (daf-16(mgDf50)I) (18 %, P = 0.00012), by pomegranate
extract in N2 (28 %, P = 0.00004) and in daf-16(mgDf50)I (10 %, P < 0.05), or by ellagic acid
(11 %, P < 0.05). Pomegranate juice reduced intestinal fat deposition (IFD) in C. elegans (n = 10)
N2 (−68 %, P = 0.0003) or in the daf-16(mgDf50)I (−33 %, P = 0.0034). The intestinal fat
deposition was increased by pomegranate extract in N2 (137 %, P < 0.0138) and in
daf-16(mgDf50)I (26 %, P = 0.0225), by ellagic acid in N2 (66 %, P < 0.0001) and in
daf-16(mgDf50)I (74 %, P < 0.0001), or by urolithin A in N2 (57 %, P = 0.0039) and in
daf-16(mgDf50)I (43 %, P = 0.0001). These effects were partially mediated by the daf-16
pathway. The data may offer insights to human aging and obesity due to homology with C.
elegans.
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ESM 1. Figure.
The estimated GAE (gallic acid equivalent, mg/ml) by calculation related to the lifespan extension at lower doses.
ESM 2. Table.
Additional statistics for lifespan (P < 0.05).
ESM 3. Table.
Calculated GAE (gallic acid equivalent) content in the doses of the PJ and POMx (extract of pomegranate juice) used in this study.
ESM 4. Table.
Correlation of estimated GAE with the dose-responses (A-shape).
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Introduction
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Health determines human lifespan as well as optimal quality of life [1, 2]. Aging at the
cellular level involves complex interacting mechanisms that lead to functional decline which
become manifest following birth and proceed through life. A U. S. population-based study
demonstrated that mortality risk was directly correlated with body mass index (BMI). Thus,
above 25 kg/m2, BMI inversely correlated with lifespan [3]. The increasing age of western
societies creates a greater burden of chronic diseases including cancer, cardiovascular
disease, diabetes, and neurodegenerative disorders including Parkinson’s disease and
Alzheimer’s disease [4, 5], leading to a high cost of health care and a great financial burden
to the public health system and families [6]. Among complex factors, both obesity and aging
decrease insulin sensitivity, impair the immune response, increase inflammation, impair the
gut-bloodstream barrier, and decrease physical mobility [7]. Many dietary interventions
provide noninvasive approaches to reinforcing optimal nutrition, fighting metabolic
dysfunction, enhancing physiological function, and promoting a healthy lifespan [8].
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Dietary polyphenol antioxidants play important roles in health [9]. Polyphenols in
blueberries extends lifespan in C. elegans [10]. Pomegranates (Punica granatum L.) juice
have a high content of polyphenols. Anthocyanins (387 mg/L), punicalagins (1561 mg/L),
ellagic acids (121 mg/L), and other hydrolyzable tannins (417 mg/L) are the major
polyphenols in PJ (Pom Wonderful) [11]. Pomegranates consist of about 80 % of juice and
20 % of seeds with water (85 %), and 10 % sugars [12, 13] (Table I). Pomegranate juice (PJ)
has been shown to extend lifespan in mice [14, 15] and Drosophila melanogaster [16], and
fructose demonstrated the similar effects in C. elegans in one of our recent studies [17]. PJ
has shown effects in controlling the condition of type 2 diabetic patients [18]. Consumption
of PJ (1.5 ml per kilograms body weight) reduces the fasting serum glucose and insulin
resistance in type 2 diabetic patients significantly [19]. Pomegranate extract (POMx)
potentiates lifespan extension with dietary restriction, a finding attributed by polyphenols
[14, 15]. POMx and PJ can also act as prebiotics, having demonstrated antibacterial
properties in vitro, and can block DNA repair and inhibit proliferation of breast cancer cells
(MCF-7) in vitro, as well as modulate the IGF-IGFBP axis [20, 21]. POMx and PJ downregulate androgen-synthesizing genes and induce apoptosis in human prostate cells (kappaBdependent) in vitro and in mice in vivo [22, 23]. POMx and PJ decrease prostate specific
antigen in humans after surgery or radiation [24, 25], inhibit tumor-associated angiogenesis
in vitro and in vivo [26], suppress inflammatory cell signaling in colon cancer cells (50
mg/L PJ, in vitro) [27], improve memory [28] and improve fecundity in humans [29].
As the main bioactive component, ellagic acid (EA) is a measure of the quality of products
[30]. EA in humans reaches a maximum plasma level in 1 hour (31.9ng/ml), is eliminated
within 4 hours [31] and exerts an antioxidant effect [32]. The colonic microflora forms the
main active metabolite of EA, urolithin A (UA). UA lasts longer in the body than EA, other
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EA metabolites [11, 33], and has better bioavailability [34]. UA also suppresses colorectal,
hepatic, and prostate cancers synergistically with EA in vitro and in mice in vivo [35, 36].
The C. elegans model-organism is the first animal model to have its genome completely
sequenced. C. elegans conserves 65 % of the genes associated with human disease, and has
more than 300 transgenic and mutant strains available for use in functional biomedical
research [37–45]. The C. elegans daf-16 gene, a homologue of the human gene FOXO,
regulates C. elegans lifespan and mediates both lipid metabolism and insulin signaling
pathways [46, 47]. Transcriptional factor skn-1 regulates lifespan in parallel to daf-16/FOXO
in the daf-2-mediated insulin/IGF-1-like signaling pathway and mutation of skn-1 is
sensitive to oxidative stress and has shorter lifespan [48]. Heat shock factor (hsf-1) also
played important role in the regulation of lifespan by regulating stress-inducible gene
expression [49].

Author Manuscript

We hypothesized that pomegranate would increase lifespan while reducing intestinal fat
deposition (IFD). We evaluated four PJ products using the C. elegans wild type (N2) to
assess their effect on lifespan, IFD using Nile red and to predict their potential effect on
aging and obesity in humans. In addition, we also used a daf-16 deficient mutant to assess
the role of the FOXO signaling pathway in mediating the effects of botanicals evaluated.

Materials and Methods

Author Manuscript

The Caenorhabditis elegans model organism is a low cost and convenient model for testing
dietary substances. C. elegans strains and their standard lab food, Escherichia coli (E. coli,
OP50, Uracil auxotroph), were obtained from the Caenorhabditis Genetics Center
(University of Minnesota, Minneapolis, MN). PJ was obtained from the first-press squeezing
of the whole pomegranate fruit (POM Wonderful® LLC, Los Angeles, CA, USA) (http://
www.pomwonderful.com/pomegranate-products/juice/100-pomegranate-juice/) and was
purchased from a local grocery store. Extraction of the remaining fruit residue obtained after
the first pressing for PJ, POMx powder was produced from a solid-phase extraction with a
high concentration of polyphenols, a gift from POM Wonderful® LLC (Los Angeles, CA,
USA). We obtained EA from Sigma (St. Louis, MO, USA). Dr. David Heber’s laboratory
synthesized the UA [11, 50].
Culture of Escherichia coli (E. coli, OP50)

Author Manuscript

We cultured the standard laboratory food of C. elegans, E. coli strain (OP50, uracil
auxotroph) by the standard method described elsewhere [44, 51, 52]. Briefly, we added
approximately 10 μL of stock E. coli solution to media and incubated at 37 °C for 24h. The
OP50 were then plated in PetrifilmTM (3M Corporate, St. Paul, MN) at 37 °C for 24h until
densities of 5×108 to 5×1011 colony forming units (cfu/ml) were reached and then were fed
to the C. elegans ad libitum [44, 53]. We added additional concentrated OP50 to the plate
every two weeks to maintain the concentration of OP50. The OP50 stock feeding solution
was enriched to 2×109cfu/ml by centrifuging at 2,200 g for 10 Minutes and washed with Scomplete buffer [54] twice.
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Mature gravid wild type C. elegans (N2, Bristol) and daf-16 deficient mutants
[daf-16(mgDf50)I] were treated with NaOH (1M) and sodium hypochlorite solution
(5.25 %, 5:2 ratio) to dissolve the body and release viable eggs [44]. The eggs hatched the
next day after washing with S-complete solution 3 times. The age-synchronized C. elegans
were diluted to 100 animals/ml, plated in liquid culture in a 96 well plate (120μl/well, 10–15
animals) [54] with OP50 (109cfu/ml), and incubated in 20 °C (N2) or 15 °C (daf-16 mutant)
low temperature incubators (Revco Tech., Nashville, NC, USA). We added thirty microliters
of 5-Fluoro-2′-deoxyuridine (FUDR, 0.6mM) stock solution to each well at L4 stage. The
C. elegans model does not require regulation of the Institutional Animal Care and Use
Committee (IACUC).
Lifespan assays

Author Manuscript

We added fifty microliters of the treatments to each well three days after eggsynchronization. The control group received OP50 only. The experimental groups received
additional PJ (0.01 %, 0.1 %, 1 %, 3 %, 5 %, 10 % or 25 %, v/v), POMx (5, 10, 20, 40, 80,
160, and 320μg/ml), EA (1, 2, 5, 10, 25, and 50μM in dimethyl sulfoxide (DMSO 0.05 %),
or UA (1, 2, 5, 10, 25, and 50μM in DMSO) (n = 10–15/well/6well). We used a second
control (DMSO, 0.05 %) in the EA and UA groups. We manually recorded the numbers of
live animals every other day under a microscope (Nikon, Eclipse Ti –S, Japan).
Fluorescence microscopy

Author Manuscript

We used the lipophilic dye, Nile red, to stain for intestinal fat deposition (IFD), and
fluorescent intensity was evaluated [44]. C. elegans in each group were collected after 3 days
of treatments, washed with S-Basal twice, fixed with paraformaldehyde (4 %) over 2h at
4 °C and washed with PBS for 5 min × 3. Nile red (50 μL) was applied to the specimens for
10 min. Ten microliters of Fluoromount-G (Southern Biotechnology Associates,
Birmingham, AL) was applied to a glass slide followed by 10 μL of the medium containing
Nile red stained C. elegans. A cover glass was mounted on the glass slide, and the slides
were viewed with an epifluorescence microscope (Nikon Eclipse, Ti) equipped with a Texas
Red filter. We randomly selected ten animal/slides, and took fluorescent micrographs with a
digital camera (Andor, DU-885k) and analyzed using Nikon-Elements (version 3.22.11).
Optical densities (arbitrary units) of Nile red stained IFD were determined for adult animals
(larvae 4).
Statistical Analysis

Author Manuscript

Analyses were carried out using SAS/STAT® software, Version 9.4 of the SAS System for
Windows (Cary, NC, USA). All results were expressed as mean ± S. E.M. Normality and
homogeneity of variance of data was checked by Shapiro-Wilk test and HOVTEST. Survival
curves were displayed by binomial probabilities obtained from logistic regression models as
surrogates for survival probabilities and mean lifespan was estimated via Kaplan-Meier (logrank). ANOVA models were used to analyze fluorescence intensity data and pairwise
differences of least squares means for different doses were compared via two-sample t-tests.
Statistical significance was defined as P < 0.05.
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Results
PJ treatment dose-dependently extended lifespan of N2 up to 56 % or daf-16 mutant up to
30 % in an A-shape curve, and decreased the magnitude of the lifespan extension at higher
doses. A similar trend with half the magnitude was seen in POMx treated animals in N2
(28 %). EA or UA did not significantly affect lifespan overall, however, lifespan extension
was observed in several days of the experiment in each treatment (ESM 2). The fluorescent
intensity of IFD in C. elegans was reduced by PJ in N2 (−68 %) or in daf-16 (−33 %). In
contrast, IFD was increased in N2 more than the daf-16 mutant by POMx (137 % at
320μg/ml vs. 26 % at 20μg/ml), or UA (57 % at 10μM vs. 43 % at 50μM). IFD was
increased by EA in N2 (66 % at 5μM and in daf-16 mutant (74 % at 25μM).
PJ dose-dependently extended then reduced lifespanin N2 and the daf-16 mutant

Author Manuscript

In a dose-dependent manner, PJ added to the cultures significantly increased mean lifespan
in N2 up to the 1 % dose but produced reduced lifespans at higher doses, an A-shape curve
relationship (Figure 1a & b). The mean lifespan was increased at lower doses (0.1 % – 1 %)
from 21 to 33 days (42 %, P = 0.00642 & 56 %, P < 0.001) while it was decreased at higher
doses (10 % & 25 %) from 33 to 4 days (−67 %, P < 0.001 & −81 %, P < 0.001) (Figure 1b).
Similarly, in the daf-16 mutant, PJ also significantly increased mean lifespan in a dosedependent manner up to 5 %, but lifespan was significantly reduced at higher doses. The
dose-response curve shifted to the right (Figure 1c). The mean lifespan of the daf-16 mutant
was increased from 27 to 32 days at a dose (5 %) that reduced lifespan in N2 (18 %, P =
0.00012) and decreased at the higher doses (−61 % at 10 %, P < 0.001 & −49 % at 25 %, P <
0.001, Figure 1b). Additionally, we observed specific days during the experiment at which
significant differences in survival probabilities, which were provided (ESM 2).

Author Manuscript

PJ dose-dependently reduced the fluorescent intensity of IFD in N2 and the daf-16 mutant
(L4). In N2, the IFD was reduced from 6971 ± 607 to 2372 ± 245 (−30 % at 1 %, P =
0.0459, −44 % at 3 %, P = 0.0052, −66 % at 5 %, P = 0.0005, −68 % at 10 %, P = 0.0003 &
−55 % at 25 %, P = 0.0028, n = 10, P < 0.05). The IFD was increased at lower doses in the
daf-16 mutant from 4677 ± 136 to 7222 ± 240 (54 % at 0.01 %, P < 0.0001 & 28 % at
0.1 %, P < 0.05, n = 10), followed by reduction at higher doses to 3134 ± 252 (−24 % at
1 %, −21 % at 5 %, P < 0.05; & −33 % at 25 %, n = 10, P = 0.0034) (Figure 1d).
POMx dose-dependently increased

Author Manuscript

A dose-response curve for lifespan extension was also present in the N2 group treated with
POMx, but was absent in the daf-16 mutant (Figure 2a). The mean lifespan was elevated
from 18 to 22 days (18 % at 10μg/ml, P = 0.00622 & 28 % at 20μg/ml, P = 0.00004, Figure
2b & 2c). The mean lifespan of the daf-16 mutant was not altered (Figure 2b). Additionally,
specific days during the experiment at which significant differences in survival probabilities
were observed are provided (ESM 2).
In N2, lower doses of POMx slightly reduced the IFD (P < 0.05) followed by an increase
from 3323 ± 63 to 7515 ± 125 at the highest dose (137 % at 320μg/ml, n = 10, P < 0.0138).
Similarly in the daf-16 mutant, POMx increased the IFD from 5012 ± 1032 to 6327 ± 716 at
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mid-dose (26 % at 20μg/ml, n = 10, P = 0.0225) followed by a reduction to 3815 ± 736 at a
higher dose (23.9 % at 80μg/ml, n = 10, P = 0.0429) (Figure 2d).
EA did not alter lifespanin N2 or in the daf-16 mutant

Author Manuscript

UA did not alter lifespanin N2 or in the daf-16 mutant

Author Manuscript

Unlike PJ and POMx that increased lifespan dose-dependently, EA did not alter lifespan in
N2 or the daf-16 mutant and the mean lifespan also being unchanged (P < 0.05, Figure 3a &
3b). The mean lifespan of the daf-16 mutant was not significant (P < 0.05, Figure 3b & 3c).
The specific days during the experiment at which significant differences in survival
probabilities were observed are provided (ESM 2). The IFD elevation by EA was dosedependent, similar in both N2 and the daf-16 mutant, and in parallel with a 2-fold elevation
in the daf-16 mutant. In N2, EA increased IFD from 5190 ± 158 to 8608 ± 323 at higher
doses (66 % at 5μM, 59 % at 10μM, 58 % at 25μM, & 47 % at 50μM, n = 10, P < 0.0001).
Similarly in the daf-16 mutant, EA increased IFD at the higher doses from 8237 ± 227 to
14324 ± 113 (60 % at 10μM, 74 % at 25μM, & 49 % at 50μM, n = 10, P < 0.0001) (Figure
3d).

Discussion

As with EA, UA did not alter the lifespan in N2 or the daf-16 mutant. In N2, the mean
lifespan was not changed (P < 0.05, Figure 4a & 4b). The mean lifespan of the daf-16
mutant seemed reduced, but the change was not significant (P < 0.05, Figure 4b & 4c).
Additionally, during the experiment, significant differences in survival probabilities were
observed within two days (ESM 2). IFD was increased in N2, from 1362 ± 61 to 6278 ± 991
in the DMSO-control group (the increase was 361 % at 0.05 % DMSO, n = 10, P < 0.05).
There was a greater increase to 9860 ± 216 at higher doses (the increase was 57 % at 10μM,
P = 0.0039, was 47 % at 25μm, P = 0.0177 and was 46 % at 50μM, P = 0.0216, n = 10). The
IFD in the daf-16 mutant was increased from 3021 ± 127 to 4324 ± 177 dose-dependently
(34 % at 10μM, P = 0.0273 & 43 % at 50μM, P = 0.0001, n = 10) (Figure 4d).

Our findings reveal that the lifespan extension has the same trend, on a larger or on a smaller
scale, in N2 and the daf-16 mutant by treatment with PJ or POMx, and has minimal effects
on lifespan in cultures treated with EA or UA. These results indicated that the daf-16
pathway was partially required for lifespan extension in the present study. We approximated
the survival curves displayed by estimated probabilities of survival across the lifespan
(Binomial). Although some treatment groups show statistically significant differences, one
cannot use comparisons based on these probabilities to draw conclusions regarding lifespan.

Author Manuscript

The maximum lifespan of N2 could be affected by the concentration of OP50 and FUDR
and as long as 58 days of lifespan in N2 is observed [55]. In a similar condition, our study
recorded the maximum 44 days of lifespan in N2 in control group, while PJ extended the
maximum lifespan of N2 to 60 days (Figure 1a).
As energy sources, appropriate amount of sugar should have beneficial effects on lifespan
extension. However, high sugar (< 2 %) in the diet is detrimental to the C. elegans and
reduces lifespan [45, 56]. We saw dose-response curves with an A-shape in PJ and POMx
Int J Vitam Nutr Res. Author manuscript; available in PMC 2020 February 04.
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treated animals, but were puzzled by the fact that the lower doses of PJ increased lifespan,
while the higher doses decreased the lifespan. We wondered if the unusual dose-response
relationship might be due to PJ’s sugar content, since fructose increases lifespan in yeast
[58], mosquitoes [59], and nematodes, while decreasing fat deposition (in nematodes) at
lower concentrations [17]. We found a reversal of the lifespan extension by PJ at a dose that
contained 0.4 % sugar. PJ has a high content of sugars in which the fructose is 1.25-fold
greater than that of glucose which, in turn, is 4.7-fold higher than that of mannitol [60]. In
agar dish culture, extra glucose (< 0.001 % or 2 %) reduces lifespan mainly due to reducing
signals of the DAF-16/FOXO and heat shock transcription factor (HSF-1) gene signaling
[61, 62]. The effect of fructose, however, is controversial. Supplemental fructose reduces the
plasma glucose level, glyco-hemoglobin, serum cholesterol, triglycerides, lactate, and body
weight in type 2 diabetes [63, 64]. Many epidemiological studies link the consumption of
high dietary fructose usage to an increased prevalence of obesity. Since associations do not
show cause and effect, we need clinical trials to support this hypothesized cause for obesity
[65, 66]. It appears that the A-shape dose-response relationship with the lifespan in the
present study relates to the increasing sugar content. On the other hand, the level of sugar
tolerance may be specie-dependent, since a diet emented with PJ (10 %) increased the
lifespan of flies [16]. Since the reduced lifespan was observed only at the highest dose in the
daf-16 mutant group, the data implies involvement of the daf-16 pathway. The A-shape
curve of PJ showed the longest lifespan to be at a sugar content of 0.13 % in N2 and 0.66 %
in the daf-16 mutant. The fact that PJ increased lifespan of the daf-16 mutant in our study
may indicate alternative mechanism. The lifespan curve shifting rightward might indicate an
“independent or compensatory effect of the daf-16 pathway”.

Author Manuscript

Fat storage is one of the outcomes of energy consumption and energy expenditure in living
organisms. In C. elegans, the fluorescent intensity of IFD of the PJ group was reduced in
both N2 and the daf-16 mutant. This inverse relationship of lifespan and fat content (PJ 1 %)
is in agreement with studies that PJ is effective in reducing cardiovascular risk factors in
overweight humans [67].

Author Manuscript

POMx is characterized by its rich polyphenol content and extended the lifespan in a similar
manner to PJ with an A-shape curve in N2. POMx in the daf-16 mutant extended lifespan by
several days (ESM 2). Unlike PJ, POMx did not reduce lifespan at higher doses. One can
attribute the results to either an absent or reduced sugar content and/or other unknown
factors. The effect of POMx on lifespan extension was only half the magnitude of the
lifespan extension induced by PJ, which suggests that multiple factors in the PJ products
extend lifespan as was suggested by the Heber’s studies [68]. Also unlike PJ, a V-shape
dose-response curve was detected for the IFD in POMx treated animals at the doses that
were used in this study, and only a minimal reduction of IFD was observed (P < 0.05). The
reversal of the pattern of increase in lifespan extension and decrease in IFD occurred at 80
mg/ml, which seems to relate to the sugar content as it did in PJ treated group. Elevating IFD
in the daf-16 mutant suggests the involvement of this pathway controlling body fat
accumulation.
Unlike either PJ or POMx, EA, at the doses used, did not alter lifespan in N2 or in the
daf-16 mutant. We observed a lifespan extension on several days of the experiment, which
Int J Vitam Nutr Res. Author manuscript; available in PMC 2020 February 04.
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was similar to a study of N2 in agar culture in which the EA (50μM at 0.3 % DMSO)
prolonged mean lifespan [51].

Author Manuscript

DMSO is a solvent that extends lifespan dose-dependently in N2 with an “A-shape” curve,
in agar culture (24 % at 0.05 % to 5 %, v/v) [69] and in a liquid culture (20 % at 0.9 %, v/v)
[70]. In the present study, DMSO doses were limited to the minimum. The lower DMSO
dose (0.05 %) extended lifespan up to 12.7 %, while the higher amount (0.1 %) decreased
the lifespan which is different from the observations of the Wang group [69], which
observed a 30 % reduction in lifespan in the daf-16 mutant (9.4 %). The effect of EA on
extending lifespan suggested complex mechanisms involving daf-16, a gene known for
lifespan in C. elegans. EA also dose-dependently increased IFD at higher doses in N2 with
parallel findings in the daf-16 mutant. The enhanced IFD in the daf-16 mutant that was not
seen in the PJ treated groups uncovered an important role of the daf-16 in lipid/energy
metabolism.

Author Manuscript

Like all polyphenols, EA’s large molecular weight and hydrophilic properties could have
limited the absorption in the intestine as well as the bioavailability to the hosts. Since the
main metabolites of EA have many beneficial effects, the effects of UA which is a
metabolite of the colonic micro-biota that has a higher absorption index has attracted
extensive research in recent years [71]. UA has anti-inflammatory, anti-carcinogenic, antiglycative, anti-oxidant, and anti-microbial effects [71–73]. In our study, some of the
treatment groups showed a statistically significant increase in mean survival probabilities in
the presence of UA. Although one cannot draw conclusions from these observations, it is
possible that higher doses of UA might alter lifespan, and the daf-16 mutant pathway may
mediate the effect of UA on lifespan. UA also dose-dependently increased IFD at higher
doses in both N2 and in the daf-16 mutant, in parallel, with the latter having half the increase
in IFD.

Author Manuscript

The antioxidant potency of PJ is higher (by at least 20 %) compared to other polyphenol-rich
products including red wine, Concord grape juice, blueberry juice, black cherry juice,
cranberry juice, orange juice, iced tea beverages, and apple juice in vitro [74]. Thus, PJ has
superior antioxidant bioactivity compared to its purified polyphenols, EA, punicalagin, or
total pomegranate tannin. The “A-shaped” dose-response curves demonstrated in this study
with PJ seemed similar to a hormesis reaction [57]. The mechanism by which a certain
dosage-range achieved an extended lifespan but reversal at a lower or higher dosage was
incompletely understood [17]. Ellagitannin comprised 90 % of the tannin polyphenols in the
POM products used in this study, but elagitannin did not extend lifespan suggesting
multifactorial effects and chemical synergy of the action of multiple compounds in PJ
compared to single purified active ingredients [68].
EA content varies by variety of the fruit, and many commercial pomegranate extracts were
found not to contain the same amount of EA [75]. We used a commercially available PJ
product , described in a full analysis of 477 commercial PJ in the market across North
America and Asia [76]. Although studies in humans the pharmacokinetics of EA and UA
that are equivalent [50], our study showed, as previously reported, that PJ was the most
potent in extending lifespan and reducing IFD with POMx being only half as potent. The
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total phenolic content, by organic phenolic acid gallic acid equivalent (GAE), are 4.7-fold
higher in PJ (2,825μg/ml GAE) than in that of POMx (606μg/mg GAE) [20]. In the present
study, the estimated GAE (mg/ml) by calculation was also directly related to the lifespan
extension at lower doses by PJ or POMx, which was reduced by higher doses (ESM 1, ESM
3, ESM 4). Thus, the fact that PJ was more potent than POMx may be beyond differences
amount of polyphenols but the synergy of various components rather than, for example, EA
only [77]. The lower or lack of effect of other tested substances compared to PJ suggest that
some effective compounds may be reduced or absent, and multifactorial effects were
present.

Author Manuscript

Our data from the C. elegans model indicate that the extension of lifespan by pomegranate is
partially dependent on the daf-16 pathway, but mechanisms other than those involving
polyphenols such as EA and its metabolites including UA may play a role as well. The
unique effects of PJ in reducing IFD suggest that the effects are due to more than one
component. The results of the C. elegans studies provide useful information and suggest
that, at the proper dilution, PJ may have optimal health benefits including control of fat
storage, prevent obesity and offer a solution to delay aging in humans.
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Figure 1.
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PJ dose-dependently increased estimated survival probabilities (displayed by binomial
probabilities obtained from logistic regression models as surrogates for survival
probabilities, binomial) and mean lifespan (estimated via Kaplan-Meier, log-rank, A-shape)
in both N2 (a & b) and daf-16 mutant (c & b) at lower doses, and dose-dependently reduced
it at higher doses (n = 6). PJ dose-dependently reduced the fluorescent intensity of IFD
(arbitrary unit) in N2 and daf-16 mutant (d, n = 10). *P < 0.05 All results were expressed as
mean ± S. E.M.
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Figure 2.
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An A-shape dose-responses of lifespan extension was present in POMx (extract of
pomegranate juice) treated group in both N2 (a & b) and the daf-16 mutant (c & b), however,
POMx was less potent than PJ. In N2, had an initial elevation of life span in the presence of
lower doses of POMx which also reduced the IFD (d, n = 6). IFD was increase at the highest
dose. In the daf-16 mutant, POMx increased IFD at mid-dose followed by a reduction at a
higher dose (n = 10). *P < 0.05 All results were expressed as mean ± S. E.M.
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Figure 3.

EA did not alter lifespan in N2 (a & b) but increased the lifespan in the daf-16 mutant (c &
b) at the highest dose (n = 6). The IFD (d) was dose-dependently elevated by EA in both N2
and daf-16 mutant, and the responses were in parallel with a greater elevation (by 2-fold) in
the daf-16 mutant (n = 10). *P < 0.05 All results were expressed as mean ± S. E.M.
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Figure 4.

The mean lifespan was increased in N2 (a & b) but decreased in daf-16 mutant (c & b) in
UA treated group (n = 6). Animals treated with UA had an increased IFD (d) in both N2 and
the daf-16 mutant with a parallel pattern of response with N2 showing a greater increase
than the daf-16 mutant (n = 10). *P < 0.05 All results were expressed as mean ± S. E.M.
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Table I.
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Phenolic content of pomegranate juice.
Phytochemical Bioactive

PJ (μg/ml)

POMX(μg/ml)
Ambient

Control

Ellagic acid (EA)

96.2

6.44+0.06

6.50+0.02

Punicalagins A&B (PA&B)

418.7

7.32 + 0.10

7.47+ 0.13

PJ : Pomegranate juice; POMX :pomegranate extract.
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